Lower Drug Dose Spells Trouble For Pharmacogenetic Test
This article was originally published in The Gray Sheet
Executive Summary
A study published in the June 20 issue of the Journal of Clinical Oncology shows that a genetic test is unnecessary in children if the cancer drug irinotecan is given in a low dose over a period of days
You may also be interested in...
FDA Clears Third Wave Invader Pharmacogenetic Test
Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.